Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Деносумаб (AMG-162) в профилактике остеопороза, вызванного приемом ингибиторов ароматазы у больных раком молочной железы в адъювантной терапии и у больных раком предстательной железы при полной андрогенной блокаде
Деносумаб (AMG-162) в профилактике остеопороза, вызванного приемом ингибиторов ароматазы у больных раком молочной железы в адъювантной терапии и у больных раком предстательной железы при полной андрогенной блокаде
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamo-xifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005; 365: 60–2.
2. Thurlimann B, Keshaviah A, Coates A et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. The Breast International Group (BIG) 1–98 Collaborative Group. N Engl J Med 2005; 353: 2747–57.
3. Coombes RC, Hall E, Snowdon C et al. The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen--updated survival analysis. Breast Cancer Res Treat 2004; 88(suppl 1): S7.
4. Jakesz R, Jonat W, Gnant M et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366: 455–62.
5. Perez E et al. Effect of Letrozole Versus Placebo on Bone Mineral Density in Women With Primary Breast Cancer Completing 5 or More Years of Adjuvant Tamoxifen: A Companion Study to NCIC CTG MA-17. J Clin Oncol 2006; 24(22): 3629–35.
6. Gnant M et al. Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer. N Engl J Med 2009; 360: 7.
7. Brufsky A et al. Integrated Analysis of Zoledronic Acid for Prevention of Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole. The Oncologist 2008; 13 (5): 503–14.
8. Lester J et al. Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer. Clin Cancer Res 2008; 14, 6336.
9. Lester J et al. Use of monthly oral ibandronate to prevent anastrozole-induced bone loss during adjuvant treatment for breast cancer: Two-year results from the ARIBON study. J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2008; 26(suppl 15): 554.
10. Anderson D et al. Nature 1997; 390: 175–9.
11. Lacey D, Timms E, Tan H et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165–76.
12. Ellis G, Bone H, Chlebowski R et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008; 26: 4875–82.
13. Smith M et al. Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer. N Engl J Med 2009; 361: 745–55.
14. Cummings S et al. Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. N Engl J Med 2009; 8: 361.
15. Powles T et al. Oral Bisphosphonates as Adjuvant Therapy for Operable Breast Cancer. Breast Cancer Res. 2006; 8: R13.
2. Thurlimann B, Keshaviah A, Coates A et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. The Breast International Group (BIG) 1–98 Collaborative Group. N Engl J Med 2005; 353: 2747–57.
3. Coombes RC, Hall E, Snowdon C et al. The Intergroup Exemestane Study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen--updated survival analysis. Breast Cancer Res Treat 2004; 88(suppl 1): S7.
4. Jakesz R, Jonat W, Gnant M et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366: 455–62.
5. Perez E et al. Effect of Letrozole Versus Placebo on Bone Mineral Density in Women With Primary Breast Cancer Completing 5 or More Years of Adjuvant Tamoxifen: A Companion Study to NCIC CTG MA-17. J Clin Oncol 2006; 24(22): 3629–35.
6. Gnant M et al. Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer. N Engl J Med 2009; 360: 7.
7. Brufsky A et al. Integrated Analysis of Zoledronic Acid for Prevention of Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole. The Oncologist 2008; 13 (5): 503–14.
8. Lester J et al. Prevention of Anastrozole-Induced Bone Loss with Monthly Oral Ibandronate during Adjuvant Aromatase Inhibitor Therapy for Breast Cancer. Clin Cancer Res 2008; 14, 6336.
9. Lester J et al. Use of monthly oral ibandronate to prevent anastrozole-induced bone loss during adjuvant treatment for breast cancer: Two-year results from the ARIBON study. J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2008; 26(suppl 15): 554.
10. Anderson D et al. Nature 1997; 390: 175–9.
11. Lacey D, Timms E, Tan H et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165–76.
12. Ellis G, Bone H, Chlebowski R et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008; 26: 4875–82.
13. Smith M et al. Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer. N Engl J Med 2009; 361: 745–55.
14. Cummings S et al. Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. N Engl J Med 2009; 8: 361.
15. Powles T et al. Oral Bisphosphonates as Adjuvant Therapy for Operable Breast Cancer. Breast Cancer Res. 2006; 8: R13.
Авторы
М.Р.Личиницер, Н.Н.Семенов
Отделение химиотерапии и комбинированного лечения злокачественных опухолей РОНЦ им. Н.Н.Блохина РАМН, Москва
Отделение химиотерапии и комбинированного лечения злокачественных опухолей РОНЦ им. Н.Н.Блохина РАМН, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.